Jacobio Pharma has announced that its subsidiary Beijing Jacobio Pharmaceuticals Co. has entered into a Capital Increase and Equity Transfer Agreement with Oceanpine Capital and an industry partner.
Under the agreement, Oceanpine Capital will acquire 80% equity interest in Beijing Jacoray Pharmaceutical Technology Co. for a total consideration of RMB 200 million (comprising RMB 125 million as the upfront payment and an additional RMB 75 million as a second instalment milestone payment).
Upon completion, Beijing Jacobio, Oceanpine Capital, and the industry partner will hold 10%, 80%, and 10% of Jacoray, respectively.
Jacoray is the project company for Jacobio's early-stage cardiovascular research programme. The transaction aligns with Jacobio's strategic focus on developing innovative oncology therapies—including KRAS and iADC —by optimising capital allocation, enhancing operational efficiency, and adopting a risk-sharing model to retain long-term project value.
Proceeds from the transaction will primarily support R&D, production, and commercialisation of Jacobio's Pan-KRAS inhibitor and other oncology assets.
Dave Chenn, Founder, CEO and Managing Partner of Oceanpine Capital, said, "Jacobio demonstrates outstanding scientific strength and strategic focus in oncology innovation. Oceanpine Capital looks forward to partnering with Jacobio to advance the globalization of China's biotech innovation."
Dr Yinxiang Wang, Chairman of Jacobio, said, "This partnership with Oceanpine Capital strengthens our strategic focus on oncology innovation and reinforces our commitment to advancing next-generation cancer therapies."
